Drug name - Afinitor

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment Nov, 2025

(3 years from now)



NOVARTIS Cancer treatment May, 2026

(3 years from now)

US9006224 NOVARTIS Neuroendocrine tumor treatment Jul, 2028

(5 years from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic


More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.